Long-term safety and efficacy of frameless subthalamic deep brain stimulation in Parkinson's disease

Neurol Sci. 2024 Feb;45(2):565-572. doi: 10.1007/s10072-023-07059-2. Epub 2023 Sep 12.

Abstract

Background: Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) is standard of care for Parkinson's disease (PD) patients and a correct lead placement is crucial to obtain good clinical outcomes. Evidence demonstrating the targeting accuracy of the frameless technique for DBS, along with the advantages for patients and clinicians, is solid, while data reporting long-term clinical outcomes for PD patients are still lacking.

Objectives: The study aims to assess the clinical safety and efficacy of frameless bilateral STN-DBS in PD patients at 5 years from surgery.

Methods: Consecutive PD patients undergoing bilateral STN-DBS with a frameless system were included in this single-center retrospective study. Clinical features, including the Unified Parkinson's Disease Rating Scale (UPDRS) in its total motor score and axial sub-scores, and pharmacological regimen were assessed at baseline, 1 year, 3 years, and 5 years after surgery. The adverse events related to the procedure, stimulation, or the presence of the hardware were systematically collected.

Results: Forty-one PD patients undergone bilateral STN-DBS implantation were included in the study and fifteen patients already completed the 5-year observation. No complications occurred during surgery and the perioperative phase, and no unexpected serious adverse event occurred during the entire follow-up period. At 5 years from surgery, there was a sustained motor efficacy of STN stimulation: STN-DBS significantly improved the off-stim UPDRS III score at 5 years by 37.6% (P < 0.001), while the dopaminergic medications remained significantly reduced compared to baseline (- 21.6% versus baseline LEDD; P = 0.036).

Conclusions: Our data support the use of the frameless system for STN-DBS in PD patients, as a safe and well-tolerated technique, with long-term clinical benefits and persistent motor efficacy at 5 years from the surgery.

Keywords: Deep brain stimulation; Frameless deep brain stimulation; Parkinson’s disease; Subthalamic nucleus.

MeSH terms

  • Deep Brain Stimulation* / adverse effects
  • Deep Brain Stimulation* / methods
  • Humans
  • Parkinson Disease* / drug therapy
  • Retrospective Studies
  • Subthalamic Nucleus* / surgery
  • Treatment Outcome